FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898090458> ?p ?o ?g. }

• W2898090458 endingPage "373" @default.
• W2898090458 startingPage "368" @default.
• W2898090458 abstract "Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR] = 1.61, 95% confidence interval [CI] = 1.08–2.39, p = 0.018), but not PFS (HR = 1.04, 95% CI 0.74–1.46, p = 0.8) or PSA response (odds ratio = 1.14, 95% CI = 0.65–1.99, p = 0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR = 0.16, 95% CI = 0.06–0.46, p < 0.001) and PFS (HR = 0.31, 95% CI = 0.12–0.80, p = 0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR-normal patients (HR = 1.93, 95% CI = 1.19–3.12, p = 0.008) and a suggestion favoring docetaxel for AR-gained patients (HR = 0.53, 95% CI = 0.24–1.16, p = 0.11). These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker." @default.
• W2898090458 created "2018-11-02" @default.
• W2898090458 creator A5000156180 @default.
• W2898090458 creator A5001474793 @default.
• W2898090458 creator A5006130493 @default.
• W2898090458 creator A5006629788 @default.
• W2898090458 creator A5008796630 @default.
• W2898090458 creator A5010040304 @default.
• W2898090458 creator A5016213425 @default.
• W2898090458 creator A5018174076 @default.
• W2898090458 creator A5028702544 @default.
• W2898090458 creator A5031994096 @default.
• W2898090458 creator A5038333200 @default.
• W2898090458 creator A5039396525 @default.
• W2898090458 creator A5042277842 @default.
• W2898090458 creator A5043277079 @default.
• W2898090458 creator A5048745498 @default.
• W2898090458 creator A5053126281 @default.
• W2898090458 creator A5056449812 @default.
• W2898090458 creator A5060049578 @default.
• W2898090458 creator A5066684629 @default.
• W2898090458 creator A5068543301 @default.
• W2898090458 creator A5070612890 @default.
• W2898090458 creator A5071060598 @default.
• W2898090458 creator A5072116005 @default.
• W2898090458 creator A5077861800 @default.
• W2898090458 creator A5085349056 @default.
• W2898090458 creator A5087812629 @default.
• W2898090458 creator A5089119498 @default.
• W2898090458 creator A5091309316 @default.
• W2898090458 date "2019-03-01" @default.
• W2898090458 modified "2023-10-18" @default.
• W2898090458 title "Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer" @default.
• W2898090458 cites W1844925317 @default.
• W2898090458 cites W2014077960 @default.
• W2898090458 cites W2067312336 @default.
• W2898090458 cites W2120292596 @default.
• W2898090458 cites W2376226802 @default.
• W2898090458 cites W2564702165 @default.
• W2898090458 cites W2608517960 @default.
• W2898090458 cites W2611922828 @default.
• W2898090458 cites W2789730857 @default.
• W2898090458 doi "https://doi.org/10.1016/j.eururo.2018.09.049" @default.
• W2898090458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6377278" @default.
• W2898090458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30773204" @default.
• W2898090458 hasPublicationYear "2019" @default.
• W2898090458 type Work @default.
• W2898090458 sameAs 2898090458 @default.
• W2898090458 citedByCount "56" @default.
• W2898090458 countsByYear W28980904582019 @default.
• W2898090458 countsByYear W28980904582020 @default.
• W2898090458 countsByYear W28980904582021 @default.
• W2898090458 countsByYear W28980904582022 @default.
• W2898090458 countsByYear W28980904582023 @default.
• W2898090458 crossrefType "journal-article" @default.
• W2898090458 hasAuthorship W2898090458A5000156180 @default.
• W2898090458 hasAuthorship W2898090458A5001474793 @default.
• W2898090458 hasAuthorship W2898090458A5006130493 @default.
• W2898090458 hasAuthorship W2898090458A5006629788 @default.
• W2898090458 hasAuthorship W2898090458A5008796630 @default.
• W2898090458 hasAuthorship W2898090458A5010040304 @default.
• W2898090458 hasAuthorship W2898090458A5016213425 @default.
• W2898090458 hasAuthorship W2898090458A5018174076 @default.
• W2898090458 hasAuthorship W2898090458A5028702544 @default.
• W2898090458 hasAuthorship W2898090458A5031994096 @default.
• W2898090458 hasAuthorship W2898090458A5038333200 @default.
• W2898090458 hasAuthorship W2898090458A5039396525 @default.
• W2898090458 hasAuthorship W2898090458A5042277842 @default.
• W2898090458 hasAuthorship W2898090458A5043277079 @default.
• W2898090458 hasAuthorship W2898090458A5048745498 @default.
• W2898090458 hasAuthorship W2898090458A5053126281 @default.
• W2898090458 hasAuthorship W2898090458A5056449812 @default.
• W2898090458 hasAuthorship W2898090458A5060049578 @default.
• W2898090458 hasAuthorship W2898090458A5066684629 @default.
• W2898090458 hasAuthorship W2898090458A5068543301 @default.
• W2898090458 hasAuthorship W2898090458A5070612890 @default.
• W2898090458 hasAuthorship W2898090458A5071060598 @default.
• W2898090458 hasAuthorship W2898090458A5072116005 @default.
• W2898090458 hasAuthorship W2898090458A5077861800 @default.
• W2898090458 hasAuthorship W2898090458A5085349056 @default.
• W2898090458 hasAuthorship W2898090458A5087812629 @default.
• W2898090458 hasAuthorship W2898090458A5089119498 @default.
• W2898090458 hasAuthorship W2898090458A5091309316 @default.
• W2898090458 hasBestOaLocation W28980904581 @default.
• W2898090458 hasConcept C121608353 @default.
• W2898090458 hasConcept C126322002 @default.
• W2898090458 hasConcept C126894567 @default.
• W2898090458 hasConcept C143998085 @default.
• W2898090458 hasConcept C151730666 @default.
• W2898090458 hasConcept C207103383 @default.
• W2898090458 hasConcept C2775832370 @default.
• W2898090458 hasConcept C2776551883 @default.
• W2898090458 hasConcept C2776694085 @default.
• W2898090458 hasConcept C2777511904 @default.
• W2898090458 hasConcept C2777899217 @default.
• W2898090458 hasConcept C2778971682 @default.
• W2898090458 hasConcept C2779343474 @default.
• W2898090458 hasConcept C2780192828 @default.

• next